ABSTRACT
Localized prostate cancer is distinctively characterized by intratumoral heterogeneity, and tumors with more complex evolutionary paths display more aggressive characteristics. In clinical trials of intense neoadjuvant androgen deprivation therapy (inADT), patients with complete or near-complete responses experience durable remissions. However, the molecular characteristics distinguishing exceptional responders and nonresponders at baseline have not been established. Here, we present the integrated histologic and genomic analysis of pre-treatment baseline tissue from our recent Phase 2 clinical study of inADT. Multiregion sampling demonstrated that patients with incomplete and nonresponding tumors demonstrate greater tumor diversity as estimated by phylogenetic tree reconstruction from DNA sequencing and automated analysis of immunohistochemical stains. Development of a four-factor binary model to predict poor response correlated with increased genomic diversity in our 37-patient cohort and a validation cohort of 188 Gleason score 8-10 prostate cancers. Together, these findings demonstrate that even in the primary setting, more highly evolved tumors have increased fitness to resist therapy.
Competing Interest Statement
H.Y. and R.T.L. perform consulting in an advisory role for Janssen Pharmaceuticals. The remaining authors declare no conflicts of interest.
Clinical Trial
NCT02430480
Funding Statement
This work was supported by the Prostate Cancer Foundation (Young Investigator Awards to S.W., S.H., F.K., D.J.Va., R.A.M., H.Y. and A.G.S.), the Department of Defense Prostate Cancer Research Program (W81XWH-19-1-0712 to S.W., W81XWH-16-1-0433 to A.G.S.), the National Cancer Institute (HHSN261200800001E) and the Intramural Research Program of the NIH, National Cancer Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This trial was approved by the Institutional Review Board of the Center for Cancer Research, National Cancer Institute (ClinicalTrials.gov identifier: NCT02430480). This study has been conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with the International Council on Harmonization guidelines on Good Clinical Practice, all applicable laws and regulatory requirements, and all conditions required by a regulatory authority and/or institutional review board. Written informed consent was obtained for all 39 patients prior to performing study-related procedures in accordance with federal and institutional guidelines.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
FINANCIAL SUPPORT This work was supported by the Prostate Cancer Foundation (Young Investigator Awards to S.W., S.H., F.K., D.J.Va., R.A.M., H.Y. and A.G.S.), the Department of Defense Prostate Cancer Research Program (W81XWH-19-1-0712 to S.W., W81XWH-16-1-0433 to A.G.S.), the National Cancer Institute (HHSN261200800001E) and the Intramural Research Program of the NIH, National Cancer Institute.
CONFLICTS OF INTEREST H.Y. and R.T.L. perform consulting in an advisory role for Janssen Pharmaceuticals. The remaining authors declare no conflicts of interest.
Tissue analysis: S.W., H.Y., N.T.T., J.R.B., N.V.C., N.C.W., R.T.L., H.A.S., M.J.M., D.C.S., H.B.K., T.L.L., A.G.S.
Data analysis: S.W., H.Y., F.K., S.A.H., N.T.T., B.J.C., S.M.W., T.L.L., D.J.Ve., B.T., A.G.S.
Manuscript writing: S.W., N.T.T., N.V.C., T.L.L., D.J.Ve., A.G.S.
Critical review and editing of the manuscript: All authors.
DATA AVAILABILITY STATEMENT Raw sequencing data depicted in Figure 1 has been deposited in the Database of Genotypes and Phenotypes (dbGaP) accession number phs001938.v2.p1. Custom code for processing data has been made available at https://github.com/CBIIT/lgcp.
Data Availability
Raw sequencing data has been deposited in the Database of Genotypes and Phenotypes (dbGaP) accession number phs001938.v2.p1.
